PGIMER marks shift to AI-driven healthcare in India

At PGIMER, Director Vivek Lal said the institute’s patient capacity has risen to 3,000 beds from 2,200 after the inauguration of two centres by Prime Minister Narendra Modi, underscoring how infrastructure expansion is still essential even as digital tools become more central. He also said the waiting list is falling despite rising patient traffic, a sign that operational improvements and capacity additions are easing bottlenecks at one of India’s best-known public hospitals.

The stronger investment case, however, is not just for hospitals. It also extends to medical technology companies, cloud and data vendors, imaging providers and robotic-surgery suppliers that stand to benefit as Indian health systems modernise. AI that helps clinicians search records, read pathology reports and interpret literature can improve productivity, but it also creates demand for better software, imaging systems and connected devices. That is where the market relevance lies: a more digital hospital is a better customer for high-end medtech.

The comments from Prof Ajit Kumar Chaturvedi, vice-chancellor of Banaras Hindu University, also pointed to a key constraint that investors and policymakers cannot ignore. AI systems trained mostly on Western datasets may not fit Indian disease patterns or clinical practice, which means domestic adoption is likely to be uneven and require local training data, validation and governance. In other words, India’s opportunity is large, but so is the risk of importing tools that do not match local realities.

That tension is visible across the healthcare technology chain. Intuitive Surgical, whose da Vinci systems rely on precision automation in operating rooms, and GE HealthCare, which sells imaging and decision-support equipment, remain exposed to the broader push toward tech-enabled care. DexCom, a leader in connected glucose monitoring, reflects the same structural shift toward continuous data and predictive models in chronic disease management. The common theme is not that AI replaces clinicians, but that it expands the amount of information and action they can manage.

For investors, the near-term question is whether AI adoption in Indian healthcare stays at the level of speeches and pilot projects or becomes embedded in procurement, workflows and reimbursement. The bull case is clear: higher throughput, lower administrative friction and better access to specialists should lift utilization and support equipment sales. The bear case is also straightforward: fragmented data, weak interoperability, uneven hospital budgets and regulatory caution could slow deployment and cap returns.

PGIMER’s anniversary message was therefore less a ceremonial nod to innovation than a snapshot of where healthcare economics is heading. The winners will be the institutions and suppliers that can turn AI from a concept into measurable clinical efficiency; the losers will be those stuck in a purely manual model as demand keeps rising.